Moreover, unlike VEGF, Ang-2 shows limited postnatal expression in normal tissues and its broad expression and prominent upregulation in tumor milieu turns it in the perfect candidate to help to define prognosis in solid tumors, besides being a suitable suspect in the game of antiangiogenic strategies [7], [25]. The gene discussed is VEGFA; the disease is neoplasm.